Arrowhead Pharmaceuticals (ARWR) CFO awarded 75,000 RSU-based shares

Rhea-AI Filing Summary

Arrowhead Pharmaceuticals’ Chief Financial Officer Daniel Joseph Apel reported an equity award of company stock. On January 6, 2026, he acquired 75,000 shares of common stock at a price of $0 per share, representing shares underlying restricted stock units. These RSUs will vest in four equal annual installments, meaning portions of the award become fully owned over four years if conditions are met. Following this grant, Apel beneficially owns 176,200 shares of common stock, which includes previously reported RSU-based holdings, some of which remain subject to vesting conditions.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Apel Daniel Joseph

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	75,000	$0.00	--

Holdings After Transaction: Common Stock — 176,200 shares (Direct)

Footnotes (1)

1. Represents shares underlying restricted stock units which will vest in four equal annual installments. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Apel Daniel Joseph

(Last) (First) (Middle)

177 E COLORADO BLVD, SUITE 700

(Street)

PASADENA CA 91105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARROWHEAD PHARMACEUTICALS, INC. [ ARWR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		A		75,000(1)	A	$0	176,200(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares underlying restricted stock units which will vest in four equal annual installments.

2. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

Remarks:

	/s/Daniel Joseph Apel	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ARWR report for its CFO?

Arrowhead Pharmaceuticals reported that Chief Financial Officer Daniel Joseph Apel acquired 75,000 shares of common stock on January 6, 2026 through a restricted stock unit grant.

How many Arrowhead (ARWR) shares did the CFO receive in this Form 4?

The CFO received 75,000 shares of common stock, represented by restricted stock units that were recorded at a $0 acquisition price.

How do the CFO’s new Arrowhead restricted stock units vest?

The filing states the 75,000 shares represent restricted stock units that will vest in four equal annual installments, spreading the award over four years.

What is the CFO’s total beneficial ownership in Arrowhead after this transaction?

After the reported transaction, Chief Financial Officer Daniel Joseph Apel beneficially owns 176,200 shares of Arrowhead common stock, including shares underlying prior RSU grants.

Does the Form 4 indicate these Arrowhead shares were bought on the open market?

No. The Form 4 shows the transaction code A at a $0 price, indicating an equity award (restricted stock units) rather than an open-market purchase.

Is any portion of the CFO’s Arrowhead share ownership still subject to vesting?

Yes. The filing notes that the 176,200 shares include common stock underlying restricted stock units, and a portion of these shares remains subject to vesting conditions.